Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate

FD Richard Hobbs1*, Maciej Banach2, Dimitri P. Mikhailidis3, Aseem Malhotra4 and Simon Capewell5

Abstract

The most prescribed medications in the world are statins, lipid modifiers that have been available for over 25 years and amongst the most investigated of all drug classes. With over a million patient years of trial data and publications in the most prestigious medical journals, it is remarkable that quite so much debate remains as to their place in healthcare. They have had a bittersweet passage, with vocal concerns over their possible risks, from suicide to cancer, and allegations that they do not work in women or the elderly, to statements that the whole published dataset, on over 200,000 patients consenting to enter trials, was fatally compromised by being industry-funded by and large. On the other side, there have been billions of dollars spent on generating their evidence base followed by promotion which has returned that investment many times over in profits, and a powerful scientific lobby that argue they are wonder drugs and that continued nihilism on their value risks patient lives. So who is right?

Keywords: Statins, Prevention, Cardiovascular disease, Debate, Evidence

Introduction

FD Richard Hobbs (Fig. 1)

In this Forum article, Banach and Mikhailidis argue that statins are well tolerated and effective in primary and secondary prevention of all the main cardiovascular events. They quote data from many trials, especially the Cholesterol Treatment Trialists’ (CTT) Collaboration. They discuss the reported high rates of adverse events associated with statins, but argue that these can be ameliorated by certain strategies to help patients stay on medication. They also tackle the perceived risks of dropping low-density lipoprotein cholesterol (LDL-C) too low, using medication on top of statins, namely ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies; the latter showing no difference in adverse events with patients achieving on-treatment LDL above or below 25 mg/ml (0.65 mmol/l), a level that would have been unachievable a few years ago. Talking of the event and mortality benefits seen in primary prevention of cardiovascular disease (CVD), they nonetheless highlight that much residual risk remains for patients, i.e. despite their potency, about 75 % of events continue to occur. They close by citing basic scientific evidence of the anti-inflammatory effects of statins on endothelial plaque.

For Malhotra and Capewell, these same data elicit a very different response. Whilst acknowledging the unequivocal benefit of statins in secondary prevention of CVD, they dispute the benefits in primary prevention, stating that there is no mortality benefit and the reductions in CVD events are not accompanied by overall reductions in disease. They further undermine the case for statins by arguing that adverse events are much underreported, or even designed out, in trials, including the CTT meta-analyses. They cite data that statins increase rates of type 2 diabetes and further quote observational data which suggest that 60 % of the half of patients who stop statins after a year of use do so because of adverse effects. They go on to argue that dietary changes are much more important for primary prevention of CVD, with a huge evidence base.

So how does the bewildered clinician make recommendations to patients when specialists disagree on the evidence base so fundamentally? Of course evidence is rarely complete and increasingly it is important for us to

© 2016 Hobbs et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
try and ‘triangulate’ data from trials with real-world data, to test whether spectrum or selection bias was possibly influential in trial populations. The limitations of trial data (run-in phases, potentially select populations included, primary focus on effectiveness, etc.) are similarly a major issue for observational data (less reliable data, can only test associations, selective populations, etc.). Our authors agree that statins have high value in secondary prevention of CVD, but disagree on the relative importance of side effects in patients taking them.

There is no doubt that the greatest risk with statins is rhabdomyolysis, occurring in 1 in 10,000 patients [1], but this is 400 times less likely to happen in patients than a gastrointestinal (GI) bleed (and 500 times less likely fatal) in those taking low-dose aspirin, an over-the-counter medication. Furthermore, this important but very rare risk is mainly confined to the sick elderly, should be diagnosed quickly, and usually settles quickly on statin cessation. However, this important risk probably amplifies the increased muscle symptoms seen with statins in the general population; muscle symptoms are a very common complaint in life and the connection with statins is widely made in the media. Analysis of routine patient data in case-control analyses suggests that myopathy rates may be doubled by statin use [2]. But such observational data are not without confounding factors. Does this distort patient perception of statins and indeed adherence to them? Adjusting reported adverse event rates in trials for the rates observed in the placebo arms of 14 primary prevention trials (46,262 participants) showed no statin-attributable symptoms, including muscle effects, although asymptomatic liver transaminase elevation was 0.4 % more frequent with statins across all trials. Serious adverse events and withdrawals were similar in both arms [3]. The regulatory drug package inserts should present such placebo-adjusted adverse event rates, in the same way that they report treatment effects over and above any placebo benefits (observed in most trials).

The other ‘big’ safety issue is the increased rate of diabetes by an absolute risk of 0.5 % (95 % CI 0.1–1 %, \( P = 0.012 \)) [3]. However, outcomes for those who progressed from an HbA1c below to above the diagnostic threshold to define new onset diabetes were the same as those not developing new onset diabetes in the trials (and we know that patients with established diabetes get even bigger risk reductions from statins in placebo-controlled trials). This is not a reason to be concerned over statins in ‘eligible for treatment’ populations.

We are unlikely to quantify adverse events much further – there is inevitable subjective weighting and interpretation of the data, which will always attract those that want to argue from one or other standpoint – and there is probably too much sediment to ever clear now.

As for benefits, this should be easier – as if! Personally, I think the data strongly point to a consistent relative risk reduction of statins across all lipid levels in contemporary populations; we have a very abnormal lipid phenotype in adults in most countries and it is therefore cost effectiveness (i.e. the absolute risk in populations) or disutility/utility arguments that should prevail. The National Institute for Health and Care Excellence (NICE), United States and European guidelines believe that the low cost of statins now means that those down to 10 %, 7.5 % or 15 % 10-year calculated CVD risk, respectively, are eligible to be offered a statin. Whether they take one is therefore a patient choice issue and we should not offer or attempt to cajole patients one way or another. For some patients, their fear of vascular disease will dominate and they may want a statin regardless of calculated risk. For others, the risk of symptoms will negate any perceived gain. What we should not pretend though is that personal CVD risk can be individually determined – our tools are crude and work at the population not personal level. Many
people at low calculated risk will die prematurely; indeed, what happened to our parents may be a very significant guide and that is not incorporated into scores. Although it may be an accurate interpretation that mortality benefits were not seen for low-risk primary prevention in the trials, there were mortality gains across all primary prevention eligible patients, and the trials only look at 5 years’ follow-up. The available evidence suggests that a mortality gain would emerge for almost everyone using a statin above a certain risk level (such as simply over 55 years old), but our health systems might not want to pay for that benefit or patients might not want to comply with chronic medication long enough to gain.

Perhaps we should listen more to what really concerns our patients and then base treatment recommendations on their preferences, without unduly swaying them against or for a statin through our own perceptions of the huge evidence base of statins. There is never likely to be another area of healthcare with as much evidence as relates to statins and CVD, and yet clinicians cannot even agree here. We all have competing interests in this debate.

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? Yes!

Maciej Banach and Dimitri P. Mikhailidis (Figs. 2 and 3)

Statins are commonly prescribed drugs [4] that are well tolerated and effectively prevent cardiovascular events both in primary and secondary prevention [5, 6]. These drugs play an essential role in patients with CVD, as they significantly reduce the risk of acute myocardial infarction (AMI), cardiovascular revascularization, stroke, cardiovascular mortality and all-cause mortality [6, 7]. It has also been shown that these effects, as well as other benefits, might be observed irrespective of LDL-C goals achieved [6, 7]. In a study involving 1,054 patients with AMI who had baseline LDL-C levels <70 mg/dl (1.8 mmol/l), further statin therapy significantly reduced the risk of the composite primary endpoint (the composite of 1-year major adverse cardiac events, including death, recurrent myocardial infarction, target vessel revascularization and coronary artery bypass grafting) by 42 % (\(P = 0.015\)) [8]. Statin therapy also reduced the risk of cardiac death (by 53 %, \(P = 0.031\)) and coronary revascularization (by 55 %, \(P = 0.013\)).

In secondary prevention, ‘the lower the better’ phenomenon has been widely discussed since important studies such as the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22) [9] trial. The debate has been associated with some doubts concerning the additional cardiovascular efficacy as well as safety of further lowering of LDL-C to levels even below 40 and 30 mg/dl (1.0 and 0.8 mmol/l) [10]. These doubts have been clarified by the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) [11] and the results of studies assessing PCSK9 inhibitors [12]. The IMPROVE-IT trial included 18,144 patients who were hospitalized for acute coronary syndrome (ACS) and had LDL-C levels of 50–100 mg/dl (1.3–2.6 mmol/l) if they were receiving lipid-lowering therapy or 50–125 mg/dl (1.3–3.2 mmol/l) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) was compared with simvastatin (40 mg) and placebo. The median LDL-C level during the study was 53.7 mg/dl (1.4 mmol/l) in the simvastatin-ezetimibe
group compared with 69.5 mg/dl (1.8 mmol/l) in the simvastatin monotherapy group ($P <0.001$) [11]. The Kaplan–Meier event rate for the primary endpoint at 7 years was $32.7\%$ in the simvastatin-ezetimibe group compared with $34.7\%$ in the simvastatin monotherapy group (absolute risk difference, hazard ratio (HR) 0.936, $P = 0.016$; number needed to treat (NNT) 50). Rates of therapy-related adverse effects (AEs) were similar in the two groups [11]. The IMPROVE-IT trial confirmed the efficacy and safety of intensive LDL-C-lowering in patients with ACS. Safety of the very low concentrations of LDL-C was also confirmed in the ODYSSEY LONG TERM trial with alirocumab added to statins, where no differences in AEs between the group with LDL-C below and over 25 mg/dl were noted [12, 13]. The available studies have also shown that the effectiveness of statin therapy, especially high-intensive regimens with rosuvastatin 20–40 mg and atorvastatin 40–80 mg, could be very high, and even in $>90\%$ of patients we might achieve lipid goals [14]. Additionally, statin therapy might not only stabilize an atheroma plaque, but also reduces its volume as well as favourably influencing other parameters of its morphology. In the recent Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group meta-analysis [15] we showed that statin therapy significantly reduces plaque volume (standard mean difference (SMD) $-0.137$, $P = 0.023$), external elastic membrane volume ($-0.097$, $P = 0.027$), fibrous plaque volume ($-0.129$, $P = 0.045$) and increases dense calcium volume ($0.229$, $P = 0.043$).

However, despite this well-established role of statin therapy in secondary prevention patients, statin use is also associated with AEs and residual risk [16, 17]. Statin-related AEs might impair the effectiveness of statin therapy. Most of the AEs are muscle-related; however, there are also other statin-associated AEs, such as sleep disorders, hair loss, gastroenterological disorders or cognitive disorders, but for many of them causality has still not been confirmed [16, 18]. It is relevant to note that patients with statin-related side effects at baseline were excluded from the trials and that knowledge is mainly based on observational cohort studies, which probably overestimate the number of patients with AEs after statin therapy [16, 18]. Statin intolerance is a real phenomenon, which can affect up to $15\%$ of patients, and knowledge of the most common AEs associated with statin therapy is crucial to ensure effective treatment of lipid disorders by reducing the risk of discontinuing statin therapy and improving therapy adherence [16, 18]. However, with careful management (take your time approach) we might successfully treat over $90\%$ of the patients previously reporting statin intolerance [16, 18].

The issue of residual risk has been widely discussed for many years, each time with the occasion of new drug development for dyslipidaemic patients [19]. According to available studies residual risk involves $50–70\%$ of patients treated with statins, and recent data from the EUROASPIRE IV survey suggest that despite the fact that the majority ($87\%$) of secondary prevention patients now receive a statin, only $21\%$ of high-risk patients have LDL-C levels below 70 mg/dl (1.8 mmol/l) and $58\%$ below 100 mg/dl (2.5 mmol/l) [20]. Several factors can influence residual risk; this is associated with patients at very high risk with concomitant diseases and polypharmacy, and the problem of significant underuse of high doses of statins – in many European countries as well as in the United States atorvastatin 80 mg or rosuvastatin 40 mg is used in $<5\%$ of dyslipidaemic patients [20–22]. Finally the question is whether we should expect that one drug (a statin) would completely reduce the overall risk? Probably the best answer to this question regarding the role of statins in secondary prevention is the fact that all available (ezetimibe, fenofibrate) and currently investigated (e.g. PCSK9 and CETP inhibitors) drugs are mainly considered for use ‘on top of’ statins.

The role of statins in primary prevention seems to also be well established [23]. The CTT meta-analysis of 14 randomized trials (90,056 individuals) showed that statins can safely reduce the 5-year incidence of major coronary events, coronary revascularization and stroke by about $12\%$ per 1 mmol/l reduction in LDL-C, irrespective of the initial lipid profile or other presenting characteristics [24]. The observed reduction in all-cause mortality (risk ratio (RR) 0.88, $P <0.0001$) reflected a $19\%$ reduction in coronary mortality (0.81, $P <0.0001$), with significant corresponding reductions in myocardial
infarction or coronary death (0.77, \( P < 0.0001 \)), in the need for coronary revascularization (0.76, \( P < 0.0001 \)), in fatal or non-fatal stroke (0.83, \( P < 0.0001 \)), and, combining these, of 21 % in any such major vascular event (0.79, \( P < 0.0001 \)) [24]. Taking all years together, the overall reduction of about one fifth per mmol/l LDL-C reduction translated into 48 fewer participants having major vascular events per 1,000 among those with pre-existing coronary heart disease (CHD) at baseline, compared with 25 per 1,000 among participants with no such history [24].

These results were confirmed in a meta-analysis that included ten trials (70,388 participants without established CVD), which showed that statins significantly reduced the risk of all-cause mortality (odds ratio (OR) 0.88), major coronary events (0.70) and major cerebrovascular events (0.81) [25]. In another analysis, Ray et al. determined whether statin therapy reduces all-cause mortality among intermediate to high-risk individuals without a history of CVD [26]. Data from 11 studies with 65,229 participants showed that use of statins in the high-risk primary prevention setting was not associated with a statistically significant reduction (RR 0.91) in the risk of all-cause mortality. These findings complement and extend the above-mentioned meta-analyses [24] as well as the results from the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial [27], which reported that statins reduced death from any cause by 12 %. However, these estimates were based on information from both individuals with and without pre-existing CHD or stroke, which may overestimate the real benefits in the primary prevention setting. Despite the continuing discussion of the effect of statins on all-cause mortality in these groups of patients, their role in primary prevention individuals, especially in high-risk ones, is unquestionable. In low and moderate-risk patients the decision regarding starting statin therapy should be assessed individually taking into account the cardiovascular risk as well as the risk of statin-related side effects (e.g. new onset diabetes, especially in patients with overweight/obesity and/or insulin resistance) [28].

Statins have been called the drugs of 21st century [6]; this is connected both with their potent lipid-lowering properties as well as pleiotropic actions (e.g. anti-inflammatory, antioxidant and antithrombotic). These off-lipid-lowering properties have been the topic of considerable discussion; possibly these properties are simply the result of intense LDL-C reduction and as a consequence decrease inflammation and oxidative stress, and stabilize atheromatous plaques [29–31]. That is why within LBPMC Group we carried out a series of meta-analyses, which aimed to answer the question regarding the pleiotropic effects of statins. Endothelial dysfunction may be associated with increased circulating asymmetric dimethylarginine (ADMA) levels, an L-arginine analogue, which inhibits nitric oxide (NO) synthesis [29]. Therefore, we assessed the effect of statins on circulating ADMA levels [29]. In the analysis of nine randomized controlled trials (RCTs) with 1,134 participants we showed a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (−0.104 \( \mu M \), \( P < 0.0001 \)) [29]. We also investigated the effect of statin therapy on circulating endothelin-1 (ET-1) levels [30]. Data from 15 RCTs showed that statin therapy significantly reduced plasma ET-1 concentrations (−0.30 pg/ml, \( P < 0.01 \)), and this effect was not affected by the duration of statin therapy (<12 weeks: −0.51 pg/ml, \( P < 0.01 \); >12 weeks: −0.19 pg/ml, \( P < 0.05 \)) or by dose of statins (<40 mg/day: −0.27 pg/ml, \( P = 0.01 \); >40 mg/day: −0.38 pg/ml, \( P = 0.01 \)) [30]. We also investigated the antithrombotic effects of statins, analysing the effect of statin therapy on D-dimer levels [31] and von Willebrand factor Antigen (vWF:Ag) [32]. In the first analysis of nine RCTs with 1,165 participants we showed a significant effect of statin therapy in reducing plasma D-dimer levels (−0.988 \( \mu g/ml \), \( P = 0.001 \)), with the effect significant only in the subsets of studies with treatment duration ≥12 weeks (−0.761 \( \mu g/ml \), \( P < 0.001 \)) and for lipophilic statins (atorvastatin and simvastatin) (−1.364 \( \mu g/ml \), \( P = 0.001 \)) [31]. In the other meta-analysis we assessed the impact of statins on vWF:Ag levels [32]. vWF is involved in platelet adhesion, coagulation factor VIII binding and transport, and formation and deposition of thrombus, and elevated vWF concentrations have been shown to be associated with endothelial dysfunction and/or injury [32]. In the meta-analysis of 21 treatment arms we showed a significant decrease in plasma vWF:Ag levels following statin therapy (SMD −0.54, \( P = 0.001 \)). In subgroup analyses, the effect size calculated for lipophilic statins was greater (−0.56, \( P = 0.003 \)) than that of hydrophilic ones (−0.38, \( P = 0.046 \)), and in the subset of studies lasting ≥12 weeks (−0.70, \( P = 0.005 \)) compared with that of studies lasting <12 weeks (−0.34, \( P = 0.052 \)) [32].

All these meta-analyses support the pleiotropic properties of statins and confirm the multifactorial mechanism of action of statins. These effects may lead to statins becoming the most important cardiovascular drugs, both in primary and secondary prevention settings.

**Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? No!**

Aseem Malhotra and Simon Capewell (Figs. 4 and 5)

The published literature states an unequivocal mortality benefit for secondary prevention – patients with
established heart disease (absolute risk reduction (ARR) 1.2 %, NNT 83) over 5 years [33]. However, the same does not apply in primary prevention, especially in individuals at low risk. Independent analysis of the largest and most comprehensive meta-analysis carried out by the CTT Collaboration revealed no mortality benefit in individuals with a <20 % risk of developing CVD in the next 10 years [34]. With no significant mortality benefit the question then moves to non-mortality benefits, and potential harms. The same large analysis suggested a 1 in 140 risk reduction in non-fatal heart attack or stroke in those with <10 % risk of CVD over 10 years but no reduction in serious illness. For truly informed decision making in the prescription of statins, we believe it is an ethical imperative to estimate both the number needed to treat (NNT) and also the number needed to harm (NNH) [35, 36].

There are clearly understandable problems when relying on industry-sponsored trials designed primarily to determine the benefits of statins, to ascertain the true incidence of side effects that may interfere with the quality of life. This partly reflects the high selectivity of participants in clinical trials. Pre-randomization run-in periods may also be used to exclude patients who fail to tolerate statins. For example, 36 % of screened patients were excluded from the Heart Protection Study before the actual trial even began, which had the potential to screen out many patients who may have suffered from adverse effects from simvastatin, including muscle symptoms [37]. In community-based studies, over half of statin users will cease to take the drug within a year, with 62 % of those patients citing side effects as the reason [38, 39]. The uncontrolled nature of these large cohort studies is clearly not ideal. However, a recent article suggesting that in industry-sponsored RCTs there are no significant differences in the rates of adverse effects between active statins versus placebo groups is unhelpful [3]. This simply adds ‘false precision to biased estimates’ [40]. These trials have not adequately assessed the most commonly reported side effects reported by patients, notably muscle pains and cognitive impairment. The head of the CTT Collaboration has recently conceded that they did not assess for all possible side effects [41]. As every practising clinician knows, such side effects are common when patients are actually asked.

A publicly funded double-blinded RCT published in the Archives of Internal Medicine involving 1,016 low-risk patients receiving simvastatin 20 mg, pravastatin 40 mg or placebo revealed that both drugs had a significant adverse effect on energy/fatigue exercise score, with
up to 40% of women reporting reduced energy or fatigue with exertion [42].

Furthermore, it is instructive to note that Pfizer’s own patient information leaflet of atorvastatin states that ‘common side effects (may affect up to 1 in 10 patients)’ of the drug include pain in the throat, nausea, indigestion, joint and muscle pain, and increases in blood sugar levels [43]. Fortunately the majority of these symptoms may be reversible on cessation of the drug. However, the small increased 0.5–1.1% risk of type 2 diabetes now directly attributed to statins should not be dismissed lightly.

Over 80% of CVD is attributable to environmental factors, notably unhealthy diet and also smoking, alcohol and physical inactivity. Diet has primacy, accounting for a larger burden of CVD disease and death than tobacco, alcohol and inactivity combined [44].

For those at low risk eating an apple a day has an equivalent risk reduction for myocardial infarction as taking a statin [45]. In a recent large primary prevention RCT for those at high risk, a Mediterranean diet supplemented with 30g of nuts daily or at least 4 tablespoons of extra virgin olive oil reduced the risk of cardiovascular events by almost a third [46]. There was an absolute risk reduction of 1.5% (NNT 61) for stroke in comparison to Mediterranean diet alone and no adverse dietary effects noted. It is likely that these benefits might have been even larger if compared to the average Western diet.

Crucially, these dietary benefits are independent of differences in LDL-C. It is the abundant alpha-linoleic acid, polyphenols and omega-3 fatty acids provided in nuts, olive oil, oily fish, vegetables and fruit that rapidly exert positive health effects by attenuating inflammation, atherosclerosis and thrombosis [47]. Concentrating on LDL-lowering alone as an end in itself might therefore be counterproductive. Indeed, insulin resistance may emerge as the single most important determinant of coronary artery disease. In young adults, preventing insulin resistance could prevent 42% of myocardial infarctions, a larger reduction than correcting hypertension (36%) [48].

It is plausible that the small benefits of statins in the prevention of CVD come from pleiotropic effects which are independent of LDL-lowering. The focus in primary prevention should therefore be on foods and food groups that have a proven benefit in reducing hard endpoints and mortality.

**Competing interests**

FDRH has acted as an occasional paid and non-paid adviser or speaker, or received expenses, to health system providers, including the National Health Service (NHS), to guideline committees and societies, including NICE and the European Society of Cardiology (ESC), and to various pharmaceutical companies with interests in CVD and statins. He is also supported by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR), NIHR Oxford Biomedical Research Centre (OxBR), NIHR Collaboration for Leadership in Applied Health Research (CLAHRC) Oxford and Harris Manchester College, Oxford, UK. MB has given lectures, received honoraria, and participated in conferences, advisory boards and clinical trials sponsored by Abbott, Abbott Vascular, Amgen, Daiichi Sankyo, MSD, Resverlogix Corporation and Sanofi-Regeneron. He has also received grant support from Valeant. DPM has given talks and attended conferences sponsored by MSD, AstraZeneca and Libytec. AM and SC have no competing interests to declare.

**Authors’ contributions**

All authors were involved in drafting, editing and revising the manuscript, and agreed to its publication. All authors read and approved the final manuscript.

**Author details**

1. Nuffield Department of Primary Care Health Sciences, Oxford, UK.
2. Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
3. Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London, London, UK.
4. Frimley Park Hospital, Surrey, UK.
5. Department of Public Health and Policy, University of Liverpool, Liverpool, UK.

Received: 1 December 2015 Accepted: 1 December 2016
Published online: 08 January 2016

**References**

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Blaha N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of 17,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
2. Macédo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51.
3. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74.
4. Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneau L, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015;95:96–111.
5. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
6. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indicators for statins? Med Sci Monit. 2009;15(12):MS1–5.
7. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):46–57.
8. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, et al. Benefit of early intensive statin therapy in patients with acute myocardial infarction who have extremely low density lipoprotein cholesterol. J Am Coll Cardiol. 2011;58(16):1664–71.
9. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Juralin P, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006;47(11):2326–31.
10. Banach M, Serban C, Aronow WS, Rysz J, Dragan S, Lemna EV, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014;46(5):947–61.
11. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.
et al. BMC Medicine 2016;14:44

12. Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther. 2015;20(2):157–68.

13. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1499–99.

14. Rizzo M, Banach M, Montalto G, Mikhailidis DP. Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci. 2012;8(4):598–600.

15. Banach M, Serban C, Sahebkar A, Mikhailidis DP, Uronson S, Ray KK, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.

16. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23.

17. Katsiki N, Nikolak D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2015;19(17):3124–31.

18. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14(6):935–55.

19. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012;51(4):314–24.

20. Koteva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutical management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015. [Epub ahead of print].

21. Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108–14.

22. Dorobantu M, Tautu OF, Darabont R, Ghiorghe S, Badila E, Dana M, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108–14.

23. Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108–14.

24. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmanski R, Pawlicki L. Objectives and methodology of Romanian SEPHAR II Survey. Project for comparing the prevalence and control of cardiovascular risk factors in two East-European countries: Romania and Poland. Arch Med Sci. 2015;11(4):715–23.

25. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.

26. nonprofit superoxide ion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol Ther. 2006;49(4):143–7.

27. Brugts JJ, Yetgin T, Hoeks SE, Goto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.

28. Ray KK, Seshasay S, Ercou P, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomised controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(1):2024–31.

29. Ididner PM, Danielson E, Fonseca FA, Genest J, Goto AM, Kasele GJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(2):2195–207.

30. Banach M, Malodobra-Mazur M, Gluba A, Barylski M, Banach M, Grycewicz J, Irzmanski R, Pawlicki L. Objectives and methodology of Romanian SEPHAR II Survey. Project for comparing the prevalence and control of cardiovascular risk factors in two East-European countries: Romania and Poland. Arch Med Sci. 2015;11(4):715–23.

31. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmanski R, Pawlicki L. Objectives and methodology of Romanian SEPHAR II Survey. Project for comparing the prevalence and control of cardiovascular risk factors in two East-European countries: Romania and Poland. Arch Med Sci. 2015;11(4):715–23.

32. Sahebkar A, Serban C, Uronson S, Mikhailidis DP, Undas A, Lip GY, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen: Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2015;113(3):564–7.

33. Sahebkar A, Serban C, Uronson S, Mikhailidis DP, Undas A, Lip GY, et al. Association between statin use and plasma D-dimer levels: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.